BioMarin Pharmaceutical Inc. is being aggressive on pricing, at least compared to analyst expectations, but realistic about a slow, measured roll-out for Palynziq (pegvaliase), its second approved drug for the rare enzymatic disorder phenylketonuria (PKU). US FDA approved the drug on May 24 and BioMarin announced pricing of $488 per unit, which it anticipates will average out to roughly $192,000 per patient annually.
Analysts generally took a positive view of the approval, even though Palynziq’s label includes a black box warning on the...
